Q2 EPS Forecast for Bausch Health Cos Decreased by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Equities research analysts at Zacks Research decreased their Q2 2027 earnings estimates for Bausch Health Cos in a research note issued on Wednesday, March 11th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $0.89 for the quarter, down from their previous estimate of $0.96. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ FY2028 earnings at $3.36 EPS.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, February 18th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.21 by ($0.13). The business had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.71 billion. Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%.

Several other equities research analysts have also recently weighed in on the company. Wall Street Zen cut Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Barclays cut their price objective on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 25th. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Weiss Ratings cut Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research report on Thursday, February 19th. Finally, Truist Financial increased their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Bausch Health Cos currently has a consensus rating of “Reduce” and a consensus target price of $8.33.

Bausch Health Cos Trading Down 0.3%

NYSE BHC traded down $0.02 during trading on Friday, hitting $5.04. 138,226 shares of the company’s stock traded hands, compared to its average volume of 2,329,587. The stock has a fifty day moving average of $6.24 and a two-hundred day moving average of $6.55. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $8.69. The firm has a market cap of $1.88 billion, a P/E ratio of 11.97 and a beta of 0.37. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.47 and a quick ratio of 1.08.

Institutional Investors Weigh In On Bausch Health Cos

A number of large investors have recently bought and sold shares of the company. Tidal Investments LLC lifted its stake in shares of Bausch Health Cos by 2.6% in the 2nd quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after purchasing an additional 1,276 shares during the period. Commonwealth Equity Services LLC boosted its holdings in shares of Bausch Health Cos by 14.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock worth $98,000 after purchasing an additional 1,812 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in shares of Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock valued at $690,000 after purchasing an additional 2,552 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its position in Bausch Health Cos by 4.6% during the fourth quarter. Squarepoint Ops LLC now owns 78,715 shares of the company’s stock worth $547,000 after buying an additional 3,495 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Key Headlines Impacting Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks raised a few near‑term estimates that provide limited support — including Q1 2027 to $0.82 (from $0.79), Q3 2027 to $1.12 (from $1.04), and small increases to Q2 2026, Q4 2026 and FY2026 (to $3.92). These upward tweaks may temper downside expectations if sustained.
• Neutral Sentiment: Portnoy Law Firm announced an investigation into Bausch + Lomb Corporation (BLCO) for possible securities fraud; that probe directly targets BLCO (NYSE: BLCO) rather than BHC, but it can create reputational or sector‑wide nervousness among investors. Bausch + Lomb Investigated
• Negative Sentiment: Zacks cut several key estimates — most notably Q2 2027 to $0.89 (from $0.96) and lowered FY2027 to $3.79 (from $3.85), along with reductions to Q3 2026 and Q4 2027 in separate notes. Multiple downward revisions signal a softer near‑term earnings outlook and are likely the principal driver of today’s share weakness.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.